Found 133 clinical trials
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:
5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.
- 0 views
- 19 Feb, 2024
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
- 0 views
- 19 Feb, 2024
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …
- 0 views
- 19 Feb, 2024
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, …
- 0 views
- 19 Feb, 2024
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.
- 0 views
- 19 Feb, 2024
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- 16 views
- 19 Feb, 2024
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
- 0 views
- 19 Feb, 2024
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.
- 0 views
- 19 Feb, 2024
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.
Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly …
- 0 views
- 19 Feb, 2024
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
This phase II study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death.
- 0 views
- 19 Feb, 2024